10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020

American Diabetes Association

doi:10.2337/dc20-s010

Cited by 487Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and Research

10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020

Open access

American Diabetes Association·2020·Diabetes Care

DOI 10.2337/dc20-s010

Open this paper in CoChat — free account Open PDF

Abstract

The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc20-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc20-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.2337/dc20-s010

Cites

179 of 179 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

SGLT2i and GLP1ra significantly reduce cardiovascular deaths independent of their effect on hyperglycemia.
“Sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1ra) are novel classes of medications for type 2 diabetes that significantly reduce cardiovascular deaths independent of their effect on hyperglycemia and are widely endorsed by clinical practice guidelines.4–11”
From Disparities in Use of Novel Diabetes Medications by Insurance: A Nationally Representative Cohort Study (2024) · cites this paper as [9]
The GLP-1 Receptor Agonist Trials section reports significant reductions in cardiovascular events with several SGLT2 inhibitors and GLP-1 receptor agonists, and recommends agents with demonstrated cardiovascular benefit for selected patients with type 2 diabetes. It does not establish that both classes significantly reduce cardiovascular deaths specifically or that those benefits are independent of their effects on hyperglycemia; the SGLT2 Inhibitor Trials section reports no difference in cardiovascular death in one trial. Page numbers were not available in our copy. (LLM, conf=0.87)
Experimental — accuracy not yet measured
SGLT2i and GLP1ra are widely endorsed by clinical practice guidelines.
“Sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1ra) are novel classes of medications for type 2 diabetes that significantly reduce cardiovascular deaths independent of their effect on hyperglycemia and are widely endorsed by clinical practice guidelines.4–11”
From Disparities in Use of Novel Diabetes Medications by Insurance: A Nationally Representative Cohort Study (2024) · cites this paper as [9]
Professional society guidelines recommend GLP-1RA therapy for cardiovascular risk mitigation in patients with type 2 diabetes and established ASCVD or multiple ASCVD risk factors, independent of glucose control or background antihyperglycemic therapy.
“Professional society guidelines now recommend GLP-1RA therapy for cardiovascular risk mitigation in patients with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD) or multiple ASCVD risk factors, independent of glucose control or background antihyperglycemic therapy (other diabetes medications being used).”
From Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review (2020) · cites this paper as [15]
Society recommendations and guidelines support the concurrent use of GLP-1RAs and SGLT2 inhibitors when needed for adequate glycemic control, but data on whether such combinations yield incremental cardiovascular advantages are lacking.
“Society recommendations and guidelines support the concurrent use of GLP-1RAs and SGLT2 inhibitors when needed for adequate glycemic control, but data on whether such combinations may yield incremental cardiovascular advantages are lackingthusfar.15,16,21”
From Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review (2020) · cites this paper as [15]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315 · see citing works
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490 · see citing works
2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8)
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950 · see citing works
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830 · see citing works
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · see citing works
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992 · see citing works
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · see citing works
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848 · see citing works
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616 · see citing works
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550 · see citing works
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325 · see citing works
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · see citing works
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138 · see citing works
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728 · see citing works
Effects on Blood Pressure of Reduced Dietary Sodium and the Dietary Approaches to Stop Hypertension (DASH) Diet
Sacks, F. M., Svetkey, L. P., Vollmer, W. M., Appel, L. J., Bray, G. A., Harsha, D., Obarzanek, E., Conlin, P. R., Miller, E. R., Simons-Morton, D. G., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101043440101 · Cited by 5,638 · see citing works
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938 · see citing works
Optimal Medical Therapy with or without PCI for Stable Coronary Disease
Boden, W. E., O'Rourke, R. A., Teo, K. K., Hartigan, P. M., Maron, D. J., Kostuk, W. J., Knudtson, M., Dada, M., Casperson, P., Harris, C. L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070829 · Cited by 4,699 · see citing works
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487 · see citing works
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129 · see citing works
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058 · see citing works
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755 · see citing works
Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis
Ettehad, D., Emdin, C. A., Kiran, A., Anderson, S. G., Callender, T., Emberson, J., Chalmers, J., Rodgers, A., & Rahimi, K. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01225-8 · Cited by 3,755 · cited 1× · see citing works
“MI, active angina, or heart failure but havenot been shown to reducemortality as blood pressure–lowering agents in the absence of these conditions (23,59).”
Background
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
(2009) · The Lancet · doi:10.1016/s0140-6736(09)60503-1 · Cited by 3,675 · see citing works
Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts
Estruch, R., Ros, E., Salas-Salvadó, J., Covas, M.-I., Corella, D., Arós, F., Gómez-Gracia, E., Ruiz-Gutiérrez, V., Fiol, M., Lapetra, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800389 · Cited by 3,616 · see citing works
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598 · see citing works
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502 · see citing works
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,489 · see citing works
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470 · see citing works
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378 · see citing works
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317 · see citing works
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67667-2 · Cited by 3,284 · see citing works
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163 · see citing works
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911 · see citing works
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908 · see citing works
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial
(2003) · The Lancet · doi:10.1016/s0140-6736(03)13636-7 · Cited by 2,876 · see citing works
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845 · see citing works
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · see citing works
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
Collaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833 · see citing works
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577 · see citing works
Economic Costs of Diabetes in the U.S. in 2017
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dci18-0007 · Cited by 2,528 · see citing works
Self-citation
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502 · see citing works
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436 · see citing works
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · see citing works
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162 · see citing works
Platelet Activation and Atherothrombosis
Davì, G., & Patrono, C. (2007) · New England Journal of Medicine · doi:10.1056/nejmra071014 · Cited by 2,135 · see citing works
Role of diabetes in congestive heart failure: The Framingham study
Kannel, W. B., Hjortland, M., & Castelli, W. P. (1974) · The American Journal of Cardiology · doi:10.1016/0002-9149(74)90089-7 · Cited by 2,090 · see citing works
Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice
Brown, M. A., Magee, L. A., Kenny, L. C., Karumanchi, S. A., McCarthy, F. P., Saito, S., Hall, D. R., Warren, C. E., Adoyi, G., & Ishaku, S. (2018) · Hypertension · doi:10.1161/hypertensionaha.117.10803 · Cited by 2,089 · see citing works
Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis
Collaborators, C. T. T. (. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60104-x · Cited by 2,081 · see citing works
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial
Patel, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61303-8 · Cited by 2,054 · see citing works
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997 · see citing works
A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805796 · Cited by 1,939 · see citing works
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934 · see citing works
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial
Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829 · see citing works
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.002 · Cited by 1,751 · see citing works
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668 · see citing works
Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
Pyörälä, K., Pedersen, T. R., Kjekshus, J., Faergeman, O., Olsson, A. G., Thorgeirsson, G., & The Scandinavian Simvastatin Survival Study (4S) Group (1997) · Diabetes Care · doi:10.2337/diacare.20.4.614 · Cited by 1,623 · see citing works
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial
Williams, B., MacDonald, T. M., Morant, S., Webb, D. J., Sever, P., McInnes, G., Ford, I., Cruickshank, J. K., Caulfield, M. J., Salsbury, J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00257-3 · Cited by 1,308 · see citing works
Effects of aspirin for primary prevention in persons with diabetes mellitus
The ASCEND Study Collaborative Group (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804988 · Cited by 1,189 · see citing works
Combined angiotensin inhibition for the treatment of diabetic nephropathy
Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303154 · Cited by 1,169 · see citing works
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly
McNeil, J. J., Wolfe, R., Woods, R. L., Tonkin, A. M., Donnan, G. A., Nelson, M. R., Reid, C. M., Lockery, J. E., Kirpach, B., Storey, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805819 · Cited by 1,139 · see citing works
Angiotensin-converting-enzyme inhibition in stable coronary artery disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa042739 · Cited by 1,123 · see citing works
Fixed-Dose Combinations Improve Medication Compliance: A Meta-Analysis
Bangalore, S., Kamalakkannan, G., Parkar, S., & Messerli, F. H. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.08.033 · Cited by 1,075 · see citing works
Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus
Buse, J. B., Ginsberg, H. N., Bakris, G. L., Clark, N. G., Costa, F., Eckel, R., Fonseca, V., Gerstein, H. C., Grundy, S., Nesto, R. W., et al. (2007) · Diabetes Care · doi:10.2337/dc07-9917 · Cited by 1,055 · see citing works
Long term mortality of mothers and fathers after pre-eclampsia: population based cohort studyPre-eclampsia and cardiovascular disease later in life: who is at risk?
Irgens, H. U., Roberts, J. M., Reisæter, L., Irgens, L. M., & Lie, R. T. (2001) · BMJ · doi:10.1136/bmj.323.7323.1213 · Cited by 1,040 · see citing works
Prognostic Value of Ambulatory and Home Blood Pressures Compared With Office Blood Pressure in the General Population: Follow-Up Results From the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) Study
Sega, R., Facchetti, R., Bombelli, M., Cesana, G., Corrao, G., Grassi, G., & Mancia, G. (2005) · Circulation · doi:10.1161/01.cir.0000160923.04524.5b · Cited by 1,009 · see citing works
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial
(2008) · The Lancet · doi:10.1016/s0140-6736(08)61242-8 · Cited by 1,000 · see citing works
Cardiovascular Events and Their Reduction With Pravastatin in Diabetic and Glucose-Intolerant Myocardial Infarction Survivors With Average Cholesterol Levels: Subgroup Analyses in the Cholesterol And Recurrent Events (CARE) Trial
Goldberg, R. B., Mellies, M. J., Sacks, F. M., Moyé, L. A., Howard, B. V., Howard, W. J., Davis, B. R., Cole, T. G., Pfeffer, M. A., & Braunwald, E. (1998) · Circulation · doi:10.1161/01.cir.98.23.2513 · Cited by 986 · see citing works
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis
Xie, X., Atkins, E., Lv, J., Bennett, A., Neal, B., Ninomiya, T., Woodward, M., MacMahon, S., Turnbull, F., Hillis, G. S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00805-3 · Cited by 980 · see citing works
Achievement of Goals in U.S. Diabetes Care, 1999–2010
Ali, M. K., Bullard, K. M., Saaddine, J. B., Cowie, C. C., Imperatore, G., & Gregg, E. W. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1213829 · Cited by 979 · see citing works
Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., Sacks, F., Murad, M. H., & Stalenhoef, A. F. H. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3213 · Cited by 887 · see citing works
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial
Gaziano, J. M., Brotons, C., Coppolecchia, R., Cricelli, C., Darius, H., Gorelick, P. B., Howard, G., Pearson, T. A., Rothwell, P. M., Ruilope, L. M., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31924-x · Cited by 883 · see citing works
Blood Pressure Lowering in Type 2 Diabetes: A Systematic Review and Meta-analysis
Emdin, C. A., Rahimi, K., Neal, B., Callender, T., Perkovic, V., & Patel, A. (2015) · JAMA · doi:10.1001/jama.2014.18574 · Cited by 854 · see citing works
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
Yusuf, S., Bosch, J., Dagenais, G., Zhu, J., Xavier, D., Liu, L., Pais, P., López-Jaramillo, P., Leiter, L. A., Dans, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1600176 · Cited by 848 · see citing works
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial
Ridker, P. M., Pradhan, A., MacFadyen, J. G., Libby, P., & Glynn, R. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61190-8 · Cited by 816 · see citing works
Cardiac Outcomes After Screening for Asymptomatic Coronary Artery Disease in Patients With Type 2 Diabetes: The DIAD Study: A Randomized Controlled Trial
Young, L. H., Wackers, F. J. T., Chyun, D. A., Davey, J. A., Barrett, E. J., Taillefer, R., Heller, G. V., Iskandrian, A. E., Wittlin, S. D., Filipchuk, N., et al. (2009) · JAMA · doi:10.1001/jama.2009.476 · Cited by 809 · see citing works
Diabetes as a risk factor for stroke in women compared with men: A systematic review and meta-analysis of 64 cohorts, including 775 385 individuals and 12 539 strokes
Peters, S. A. E., Huxley, R. R., & Woodward, M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60040-4 · Cited by 805 · see citing works
Detection of Silent Myocardial Ischemia in Asymptomatic Diabetic Subjects
Wackers, F. J. T., Young, L. H., Inzucchi, S. E., Chyun, D. A., Davey, J. A., Barrett, E. J., Taillefer, R., Wittlin, S. D., Heller, G. V., Filipchuk, N., et al. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.1954 · Cited by 791 · see citing works
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Furtado, R. H. M., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.038868 · Cited by 781 · see citing works
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
Zannad, F., Cannon, C. P., Cushman, W. C., Bakris, G. L., Menon, V., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62225-x · Cited by 757 · see citing works
Diabetes and hypertension: a position statement by the American Diabetes Association
de Boer, I. H., Bangalore, S., Benetos, A., Davis, A. M., Michos, E. D., Muntner, P., Rossing, P., Zoungas, S., & Bakris, G. (2017) · Diabetes Care · doi:10.2337/dci17-0026 · Cited by 714 · see citing works
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial
Bakris, G. L., Agarwal, R., Chan, J. C., Cooper, M. E., Gansevoort, R. T., Haller, H., Remuzzi, G., Rossing, P., Schmieder, R. E., Nowack, C., et al. (2015) · JAMA · doi:10.1001/jama.2015.10081 · Cited by 708 · see citing works
Antihypertensive drug therapy for mild to moderate hypertension during pregnancy
Abalos, E., Duley, L., & Steyn, D. W. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002252.pub3 · Cited by 705 · see citing works
Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events
Peters, S. A. E., Huxley, R. R., & Woodward, M. (2014) · Diabetologia · doi:10.1007/s00125-014-3260-6 · Cited by 701 · see citing works
Less-Tight versus Tight Control of Hypertension in Pregnancy
Magee, L. A., von Dadelszen, P., Rey, E., Ross, S., Asztalos, E., Murphy, K. E., Menzies, J., Sanchez, J., Singer, J., Gafni, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1404595 · Cited by 672 · see citing works
Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data
(2014) · The Lancet · doi:10.1016/s0140-6736(14)61212-5 · Cited by 623 · see citing works
Prognostic value of coronary artery calcium screening in subjects with and without diabetes
Raggi, P., Shaw, L. J., Berman, D. S., & Callister, T. Q. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.09.068 · Cited by 608 · see citing works
Validation of the Atherosclerotic Cardiovascular Disease Pooled Cohort Risk Equations
Muntner, P., Colantonio, L. D., Cushman, M., Goff, D. C., Howard, G., Howard, V. J., Kissela, B., Levitan, E. B., Lloyd-Jones, D. M., & Safford, M. M. (2014) · JAMA · doi:10.1001/jama.2014.2630 · Cited by 603 · see citing works
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
Sabatine, M. S., Leiter, L. A., Wiviott, S. D., Giugliano, R. P., Deedwania, P., De Ferrari, G. M., Murphy, S. A., Kuder, J. F., Gouni-Berthold, I., Lewis, B. S., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30313-3 · Cited by 603 · see citing works
Atenolol in hypertension: is it a wise choice?
Carlberg, B., Samuelsson, O., & Lindholm, L. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17355-8 · Cited by 562 · see citing works
Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes
Knopp, R. H., d’Emden, M., Smilde, J. G., Pocock, S. J., & on behalf of the ASPEN Study Group (2006) · Diabetes Care · doi:10.2337/dc05-2415 · Cited by 550 · see citing works
Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes
Shepherd, J., Barter, P., Carmena, R., Deedwania, P., Fruchart, J.-C., Haffner, S., Hsia, J., Breazna, A., LaRosa, J., Grundy, S., et al. (2006) · Diabetes Care · doi:10.2337/dc05-2465 · Cited by 525 · see citing works
Type 1 Diabetes Mellitus and Cardiovascular Disease
de Ferranti, S. D., de Boer, I. H., Fonseca, V. A., Fox, C. S., Golden, S. H., Lavie, C. J., Magge, S. N., Marx, N., McGuire, D. K., Orchard, T. J., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000034 · Cited by 504 · see citing works
Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry
Cavender, M. A., Steg, P. G., Smith, S. C., Eagle, K., Ohman, E. M., Goto, S., Kuder, J., Im, K., Wilson, P. W. F., & Bhatt, D. L. (2015) · Circulation · doi:10.1161/circulationaha.114.014796 · Cited by 501 · see citing works
Cognitive function in a randomized trial of evolocumab
Giugliano, R. P., Mach, F., Zavitz, K., Kurtz, C., Im, K., Kanevsky, E., Schneider, J., Wang, H., Keech, A., Pedersen, T. R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701131 · Cited by 492 · see citing works
Primary and Secondary Prevention of Cardiovascular Disease
Vandvik, P. O., Lincoff, A. M., Gore, J. M., Gutterman, D. D., Sonnenberg, F. A., Alonso-Coello, P., Akl, E. A., Lansberg, M. G., Guyatt, G. H., & Spencer, F. A. (2012) · Chest · doi:10.1378/chest.11-2306 · Cited by 476 · see citing works
High-Density Lipoprotein as a Therapeutic Target: A Systematic Review
Singh, I. M., Shishehbor, M. H., & Ansell, B. J. (2007) · JAMA · doi:10.1001/jama.298.7.786 · Cited by 468 · see citing works
Pharmacogenetic Study of Statin Therapy and Cholesterol Reduction
Chasman, D. I. (2004) · JAMA · doi:10.1001/jama.291.23.2821 · Cited by 453 · see citing works
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
Filippatos, G. S., Anker, S. D., Böhm, M., Gheorghiade, M., Køber, L., Krum, H., Maggioni, A. P., Ponikowski, P. P., Voors, A. A., Zannad, F. M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw132 · Cited by 445 · see citing works
Aspirin Dose for the Prevention of Cardiovascular Disease: A Systematic Review
Campbell, C. L., Smyth, S., Montalescot, G., & Steinhubl, S. R. (2007) · JAMA · doi:10.1001/jama.297.18.2018 · Cited by 444 · see citing works
Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis
Rajpathak, S. N., Kumbhani, D. J., Crandall, J., Barzilai, N., Alderman, M., & Ridker, P. M. (2009) · Diabetes Care · doi:10.2337/dc09-0738 · Cited by 439 · see citing works
Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)
Giugliano, R. P., Cannon, C. P., Blazing, M. A., Nicolau, J. C., Corbalán, R., Špinar, J., Park, J.-G., White, J. A., Bohula, E. A., & Braunwald, E. (2018) · Circulation · doi:10.1161/circulationaha.117.030950 · Cited by 427 · see citing works
Improved clinical outcomes associated with metformin in patients with diabetes and heart failure
Eurich, D. T., Majumdar, S. R., McAlister, F. A., Tsuyuki, R. T., & Johnson, J. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.10.2345 · Cited by 419 · see citing works
Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials
De Berardis, G., Sacco, M., Strippoli, G. F. M., Pellegrini, F., Graziano, G., Tognoni, G., & Nicolucci, A. (2009) · BMJ · doi:10.1136/bmj.b4531 · Cited by 395 · see citing works
Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis
Palmer, S. C., Mavridis, D., Navarese, E., Craig, J. C., Tonelli, M., Salanti, G., Wiebe, N., Ruospo, M., Wheeler, D. C., & Strippoli, G. F. M. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62459-4 · Cited by 395 · see citing works
Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy
Anand, D. V., Lim, E., Hopkins, D., Corder, R., Shaw, L. J., Sharp, P., Lipkin, D., & Lahiri, A. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi808 · Cited by 392 · see citing works
Reduction in Cardiovascular Events With Atorvastatin in 2,532 Patients With Type 2 Diabetes
Sever, P. S., Poulter, N. R., Dahlöf, B., Wedel, H., Collins, R., Beevers, G., Caulfield, M., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1151 · Cited by 390 · see citing works
Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin
Jones, P. H., & Davidson, M. H. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.08.076 · Cited by 387 · see citing works
Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: a systematic review and meta-analysis
Huxley, R. R., Peters, S. A. E., Mishra, G. D., & Woodward, M. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70248-7 · Cited by 383 · see citing works
Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum
Cefalu, W. T., Kaul, S., Gerstein, H. C., Holman, R. R., Zinman, B., Skyler, J. S., Green, J. B., Buse, J. B., Inzucchi, S. E., Leiter, L. A., et al. (2017) · Diabetes Care · doi:10.2337/dci17-0057 · Cited by 382 · see citing works
Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses
Brunström, M., & Carlberg, B. (2016) · BMJ · doi:10.1136/bmj.i717 · Cited by 375 · see citing works
Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract
Mach, F., Ray, K. K., Wiklund, O., Corsini, A., Catapano, A. L., Bruckert, E., De Backer, G., Hegele, R. A., Hovingh, G. K., Jacobson, T. A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy182 · Cited by 370 · see citing works
Heart failure with preserved ejection fraction: from mechanisms to therapies
Lam, C. S. P., Voors, A. A., de Boer, R. A., Solomon, S. D., & van Veldhuisen, D. J. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy301 · Cited by 355 · see citing works
Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials
Rothwell, P. M., Cook, N. R., Gaziano, J. M., Price, J. F., Belch, J. F. F., Roncaglioni, M. C., Morimoto, T., & Mehta, Z. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31133-4 · Cited by 353 · see citing works
2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Eckel, R. H., Jakicic, J. M., Ard, J. D., Jesus, J. M. D., Miller, N. H., Hubbard, V. S., Lee, I.-M. M., Lichtenstein, A. H., Loria, C. M., Millen, B. E., et al. (2014) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · Cited by 343 · see citing works
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Baglioni, P. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1902837 · Cited by 316 · see citing works
Clinical usefulness and cost effectiveness of home blood pressure telemonitoring: meta-analysis of randomized controlled studies
Omboni, S., Gazzola, T., Carabelli, G., & Parati, G. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e32835ca8dd · Cited by 313 · see citing works
A meta-analysis of the association of estimated GFR, albuminuria, diabetes mellitus, and hypertension with acute kidney injury
James, M. T., Grams, M. E., Woodward, M., Elley, C. R., Green, J. A., Wheeler, D. C., de Jong, P., Gansevoort, R. T., Levey, A. S., Warnock, D. G., et al. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.02.338 · Cited by 309 · see citing works
2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
Das, S. R., Everett, B. M., Birtcher, K. K., Brown, J. M., Cefalu, W. T., Januzzi, J. L., Kalyani, R. R., Kosiborod, M., Magwire, M. L., Morris, P. B., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.09.020 · Cited by 300 · see citing works
Pravastatin and cognitive function in the elderly. Results of the PROSPER study
Trompet, S., Vliet, P., Craen, A. J. M., Jolles, J., Buckley, B. M., Murphy, M. B., Ford, I., Macfarlane, P. W., Sattar, N., Packard, C. J., et al. (2010) · Journal of Neurology · doi:10.1007/s00415-009-5271-7 · Cited by 291 · see citing works
Coronary calcium measurement improves prediction of cardiovascular events in asymptomatic patients with type 2 diabetes: the PREDICT study
Elkeles, R. S., Godsland, I. F., Feher, M. D., Rubens, M. B., Roughton, M., Nugara, F., Humphries, S. E., Richmond, W., Flather, M. D., & for the PREDICT Study Group (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn279 · Cited by 261 · see citing works
Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials
Zhang, X.-L., Zhu, Q.-Q., Zhu, L., Chen, J.-Z., Chen, Q.-H., Li, G.-N., Xie, J., Kang, L.-N., & Xu, B. (2015) · BMC Medicine · doi:10.1186/s12916-015-0358-8 · Cited by 260 · see citing works
Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial
Margolis, K. L., O’Connor, P. J., Morgan, T. M., Buse, J. B., Cohen, R. M., Cushman, W. C., Cutler, J. A., Evans, G. W., Gerstein, H. C., Grimm, R. H., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2334 · Cited by 259 · see citing works
Screening for coronary artery disease in patients with diabetes
Bax, J. J., Young, L. H., Frye, R. L., Bonow, R. O., Steinberg, H. O., & Barrett, E. J. (2007) · Diabetes Care · doi:10.2337/dc07-9927 · Cited by 251 · see citing works
Statins and Cognitive Function: A Systematic Review
Richardson, K., Schoen, M., French, B., Umscheid, C. A., Mitchell, M. D., Arnold, S. E., Heidenreich, P. A., Rader, D. J., & deGoma, E. M. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-10-201311190-00007 · Cited by 250 · see citing works
Detection of Coronary Artery Disease in Asymptomatic Patients With Type 2 Diabetes Mellitus
Scognamiglio, R., Negut, C., Ramondo, A., Tiengo, A., & Avogaro, A. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.10.008 · Cited by 249 · see citing works
Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes
Weber, M. A., Bakris, G. L., Jamerson, K., Weir, M., Kjeldsen, S. E., Devereux, R. B., Velazquez, E. J., Dahlöf, B., Kelly, R. Y., Hua, T. A., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.046 · Cited by 244 · see citing works
Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials
Makani, H., Bangalore, S., Desouza, K. A., Shah, A., & Messerli, F. H. (2013) · BMJ · doi:10.1136/bmj.f360 · Cited by 244 · see citing works
Incidence of Hospitalization for Heart Failure and Case-Fatality Among 3.25 Million People With and Without Diabetes Mellitus
McAllister, D. A., Read, S. H., Kerssens, J., Livingstone, S., McGurnaghan, S., Jhund, P., Petrie, J., Sattar, N., Fischbacher, C., Kristensen, S. L., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034986 · Cited by 244 · cited 1× · see citing works
“Recent studies have found that rates of incident heart failure hospitalization (adjustedforageandsex)weretwofoldhigherinpatientswithdiabetescomparedwiththose without (5,6).”
Background
Use of Coronary Artery Calcium Testing to Guide Aspirin Utilization for Primary Prevention: Estimates From the Multi-Ethnic Study of Atherosclerosis
Miedema, M. D., Duprez, D. A., Misialek, J. R., Blaha, M. J., Nasir, K., Silverman, M. G., Blankstein, R., Budoff, M. J., Greenland, P., & Folsom, A. R. (2014) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.113.000690 · Cited by 242 · see citing works
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial
Fitchett, D., Butler, J., van de Borne, P., Zinman, B., Lachin, J. M., Wanner, C., Woerle, H. J., Hantel, S., George, J. T., Johansen, O. E., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx511 · Cited by 242 · see citing works
A Simplified Approach to the Treatment of Uncomplicated Hypertension: A Cluster Randomized, Controlled Trial
Feldman, R. D., Zou, G. Y., Vandervoort, M. K., Wong, C. J., Nelson, S. A. E., & Feagan, B. G. (2009) · Hypertension · doi:10.1161/hypertensionaha.108.123455 · Cited by 239 · see citing works
Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS–TIMI 54
Bhatt, D. L., Bonaca, M. P., Bansilal, S., Angiolillo, D. J., Cohen, M., Storey, R. F., Im, K., Murphy, S. A., Held, P., Braunwald, E., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.529 · Cited by 216 · see citing works
Coronary Artery Calcium Score for Long-term Risk Classification in Individuals With Type 2 Diabetes and Metabolic Syndrome From the Multi-Ethnic Study of Atherosclerosis
Malik, S., Zhao, Y., Budoff, M., Nasir, K., Blumenthal, R. S., Bertoni, A. G., & Wong, N. D. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.4191 · Cited by 215 · see citing works
Influence of Time of Day of Blood Pressure–Lowering Treatment on Cardiovascular Risk in Hypertensive Patients With Type 2 Diabetes
Hermida, R. C., Ayala, D. E., Mojón, A., & Fernández, J. R. (2011) · Diabetes Care · doi:10.2337/dc11-0297 · Cited by 213 · see citing works
Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system
Nilsson, E., Gasparini, A., Ärnlöv, J., Xu, H., Henriksson, K. M., Coresh, J., Grams, M. E., & Carrero, J. J. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.07.035 · Cited by 211 · see citing works
Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 – Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials
Thomopoulos, C., Parati, G., & Zanchetti, A. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001276 · Cited by 206 · see citing works
Aspirin, Statins, or Both Drugs for the Primary Prevention of Coronary Heart Disease Events in Men: A Cost–Utility Analysis
Pignone, M., Earnshaw, S., Tice, J. A., & Pletcher, M. J. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-5-200603070-00007 · Cited by 204 · see citing works
Atherothrombotic risk stratification and ezetimibe for secondary prevention
Bohula, E. A., Morrow, D. A., Giugliano, R. P., Blazing, M. A., He, P., Park, J.-G., Murphy, S. A., White, J. A., Kesaniemi, Y. A., Pedersen, T. R., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.070 · Cited by 204 · see citing works
Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials
Bangalore, S., Fakheri, R., Toklu, B., & Messerli, F. H. (2016) · BMJ · doi:10.1136/bmj.i438 · Cited by 183 · see citing works
Hyperkalemia after initiating renin-angiotensin system blockade: the Stockholm Creatinine Measurements (SCREAM) project
Bandak, G., Sang, Y., Gasparini, A., Chang, A. R., Ballew, S. H., Evans, M., Arnlov, J., Lund, L. H., Inker, L. A., Coresh, J., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005428 · Cited by 181 · see citing works
Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal ( <scp>CANVAS‐R</scp> ): A randomized, placebo‐controlled trial
Neal, B., Perkovic, V., Matthews, D. R., Mahaffey, K. W., Fulcher, G., Meininger, G., Erondu, N., Desai, M., Shaw, W., Vercruysse, F., et al. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12829 · Cited by 174 · see citing works
Risk score overestimation: the impact of individual cardiovascular risk factors and preventive therapies on the performance of the American Heart Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in a modern multi-ethnic cohort
DeFilippis, A. P., Young, R. L., McEvoy, J. W., Michos, E. D., Sandfort, V., Kronmal, R. A., McClelland, R. L., & Blaha, M. J. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw301 · Cited by 169 · see citing works
Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction
Bohula, E. A., Bonaca, M. P., Braunwald, E., Aylward, P. E., Corbalan, R., De Ferrari, G. M., He, P., Lewis, B. S., Merlini, P. A., Murphy, S. A., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.019861 · Cited by 168 · see citing works
Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial
Moriarty, P. M., Jacobson, T. A., Bruckert, E., Thompson, P. D., Guyton, J. R., Baccara-Dinet, M. T., & Gipe, D. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.09.007 · Cited by 154 · see citing works
Blood pressure targets for hypertension in people with diabetes mellitus
Arguedas, J. A., Leiva, V., & Wright, J. M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008277.pub2 · Cited by 151 · see citing works
Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis
Zhang, C., Sun, A., Zhang, P., Wu, C., Zhang, S., Fu, M., Wang, K., Zou, Y., & Ge, J. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.09.029 · Cited by 150 · see citing works
Sex Differences in Diabetes and Risk of Incident Coronary Artery Disease in Healthy Young and Middle-Aged Adults
Kalyani, R. R., Lazo, M., Ouyang, P., Turkbey, E. B., Chevalier, K., Brancati, F. L., Becker, D. M., & Vaidya, D. M. (2013) · Diabetes Care · doi:10.2337/dc13-1755 · Cited by 138 · see citing works
Resolution of Asymptomatic Myocardial Ischemia in Patients With Type 2 Diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) Study
Wackers, F. J. T., Chyun, D. A., Young, L. H., Heller, G. V., Iskandrian, A. E., Davey, J. A., Barrett, E. J., Taillefer, R., Wittlin, S. D., Filipchuk, N., et al. (2007) · Diabetes Care · doi:10.2337/dc07-1250 · Cited by 137 · see citing works
Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials
Beddhu, S., Greene, T., Boucher, R., Cushman, W. C., Wei, G., Stoddard, G., Ix, J. H., Chonchol, M., Kramer, H., Cheung, A. K., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30099-8 · Cited by 128 · see citing works
Is "Isolated Home" Hypertension as Opposed to "Isolated Office" Hypertension a Sign of Greater Cardiovascular Risk?
Bobrie, G., Genès, N., Vaur, L., Clerson, P., Vaisse, B., Mallion, J.-M., & Chatellier, G. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.18.2205 · Cited by 117 · see citing works
Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP
Buckley, L. F., Dixon, D. L., Wohlford, G. F., Wijesinghe, D. S., Baker, W. L., & Tassell, B. W. V. (2017) · Diabetes Care · doi:10.2337/dc17-1366 · Cited by 116 · see citing works
Evening versus morning dosing regimen drug therapy for hypertension
Zhao, P., Xu, P., Wan, C., & Wang, Z. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004184.pub2 · Cited by 113 · see citing works
Cardiovascular and Renal Outcomes of Renin–Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses
Catalá-López, F., Macías Saint-Gerons, D., González-Bermejo, D., Rosano, G. M., Davis, B. R., Ridao, M., Zaragoza, A., Montero-Corominas, D., Tobías, A., de la Fuente-Honrubia, C., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1001971 · Cited by 109 · see citing works
Achieving Goal Blood Pressure in Patients With Type 2 Diabetes: Conventional Versus Fixed‐Dose Combination Approaches
Bakris, G. L., Weir, M. R., & on behalf of the Study of Hypertension and the Efficacy of Lotrel in Diabetes (SHIELD) Investigators (2003) · The Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2002.2041.x · Cited by 94 · see citing works
The relation of serum potassium concentration with cardiovascular events and mortality in community-living individuals
Hughes-Austin, J. M., Rifkin, D. E., Beben, T., Katz, R., Sarnak, M. J., Deo, R., Hoofnagle, A. N., Homma, S., Siscovick, D. S., Sotoodehnia, N., et al. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06290616 · Cited by 92 · see citing works
Syncope, Hypotension, and Falls in the Treatment of Hypertension: Results from the Randomized Clinical Systolic Blood Pressure Intervention Trial
Sink, K. M., Evans, G. W., Shorr, R. I., Bates, J. T., Berlowitz, D., Conroy, M. B., Felton, D. M., Gure, T., Johnson, K. C., Kitzman, D., et al. (2018) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15236 · Cited by 92 · see citing works
Prognostic Value of Coronary Computed Tomographic Angiography in Diabetic Patients Without Known Coronary Artery Disease
Hadamitzky, M., Hein, F., Meyer, T., Bischoff, B., Martinoff, S., Schömig, A., & Hausleiter, J. (2010) · Diabetes Care · doi:10.2337/dc09-2104 · Cited by 90 · see citing works
Impact of Cardiovascular Risk on the Relative Benefit and Harm of Intensive Treatment of Hypertension
Phillips, R. A., Xu, J., Peterson, L. E., Arnold, R. M., Diamond, J. A., & Schussheim, A. E. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.01.074 · Cited by 88 · cited 1× · see citing works
“Absolute benefit from blood pressure reduction correlated with absolute baseline cardiovascular risk in SPRINT and in earlier clinical trials conducted at higher baseline blood pressure levels (11,37).”
Result
Beta Blocker Use After Acute Myocardial Infarction in the Patient with Normal Systolic Function: When is it “Ok” to Discontinue?
Kezerashvili, A., Marzo, K. P., & Leon, J. D. (2012) · Current Cardiology Reviews · doi:10.2174/157340312801215764 · Cited by 81 · see citing works
Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials
Basu, S., Sussman, J. B., Rigdon, J., Steimle, L., Denton, B. T., & Hayward, R. A. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002410 · Cited by 77 · see citing works
Cardiovascular Outcomes Using Doxazosin vs. Chlorthalidone for the Treatment of Hypertension in Older Adults With and Without Glucose Disorders: A Report From the ALLHAT Study
Barzilay, J. I., Davis, B. R., Bettencourt, J., Margolis, K. L., Goff, D. C., Black, H., Habib, G., Ellsworth, A., Force, R. W., Wiegmann, T., et al. (2004) · The Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2004.03216.x · Cited by 70 · see citing works
The Implications of Blood Pressure Measurement Methods on Treatment Targets for Blood Pressure
Bakris, G. L. (2016) · Circulation · doi:10.1161/circulationaha.116.022536 · Cited by 69 · see citing works
Statins for primary prevention of cardiovascular disease
French, L., & Smith, J. W. (2012) · Australian Prescriber · doi:10.18773/austprescr.2012.034 · Cited by 66 · see citing works
Metformin in Heart Failure
Inzucchi, S. E., Masoudi, F. A., & McGuire, D. K. (2007) · Diabetes Care · doi:10.2337/dc07-1686 · Cited by 64 · see citing works
Assessment of Subclinical Coronary Atherosclerosis in Asymptomatic Patients With Type 2 Diabetes Mellitus With Single Photon Emission Computed Tomography and Coronary Computed Tomography Angiography
Choi, E.-K., Chun, E. J., Choi, S.-I., Chang, S.-A., Choi, S.-H., Lim, S., Rivera, J. J., Nasir, K., Blumenthal, R. S., Jang, H.-C., et al. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.05.026 · Cited by 57 · see citing works
Individualizing Blood Pressure Targets for People With Diabetes and Hypertension: Comparing the ADA and the ACC/AHA Recommendations
de Boer, I. H., Bakris, G., & Cannon, C. P. (2018) · JAMA · doi:10.1001/jama.2018.0642 · Cited by 54 · see citing works
In Vivo Platelet Activation and Aspirin Responsiveness in Type 1 Diabetes
Zaccardi, F., Rizzi, A., Petrucci, G., Ciaffardini, F., Tanese, L., Pagliaccia, F., Cavalca, V., Ciminello, A., Habib, A., Squellerio, I., et al. (2016) · Diabetes · doi:10.2337/db15-0936 · Cited by 53 · see citing works
Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Trials
Lincoff, A. M., Wolski, K., Nicholls, S. J., & Nissen, S. E. (2007) · JAMA · doi:10.1001/jama.298.10.1180 · Cited by 52 · see citing works
Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study
Meek, C., Wierzbicki, A. S., Jewkes, C., Twomey, P. J., Crook, M. A., Jones, A., & Viljoen, A. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.657302 · Cited by 52 · see citing works
Renal denervation for the treatment of resistant hypertension: review and clinical perspective
Iliescu, R., Lohmeier, T. E., Tudorancea, I., Laffin, L., & Bakris, G. L. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00246.2015 · Cited by 50 · see citing works
Determinants of Reduced Antiplatelet Effect of Aspirin in Patients with Stable Coronary Artery Disease
Larsen, S. B., Grove, E. L., Neergaard‐Petersen, S., Würtz, M., Hvas, A., & Kristensen, S. D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126767 · Cited by 49 · see citing works
Evening‐ versus morning‐dosing‐regimen drug therapy for hypertension
(2011) · Prescriber · doi:10.1002/psb.830 · Cited by 48 · see citing works
Intensive blood pressure lowering in patients with and patients without type 2 diabetes: A pooled analysis from two randomized trials
Brouwer, T. F., Vehmeijer, J. T., Kalkman, D. N., Berger, W. R., van den Born, B.-J. H., Peters, R. J., & Knops, R. E. (2018) · Diabetes Care · doi:10.2337/dc17-1722 · Cited by 44 · see citing works
Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease
Mora, S., Ames, J. M., & Manson, J. E. (2016) · JAMA · doi:10.1001/jama.2016.8362 · Cited by 41 · see citing works
Use of diuretics during pregnancy.
Al-Balas, M., Bozzo, P., & Einarson, A. (2009) · PubMed Central · Cited by 35 · see citing works
Mineralocorticoid Receptor Blockade in Chronic Kidney Disease
Bomback, A. S., & Klemmer, P. J. (2012) · Blood Purification · doi:10.1159/000334161 · Cited by 28 · see citing works
Value of Coronary Computed Tomography Angiography in Tailoring Aspirin Therapy for Primary Prevention of Atherosclerotic Events in Patients at High Risk With Diabetes Mellitus
Dimitriu‐Leen, A. C., Scholte, A. J. H. A., van Rosendael, A. R., van den Hoogen, I. J., Kharagjitsingh, A. V., Wolterbeek, R., Knuuti, J. M., Kroft, L. J. M., Delgado, V., Jukema, J. W., et al. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.12.023 · Cited by 25 · see citing works
Reevaluating the Evidence for Blood Pressure Targets in Type 2 Diabetes
Lamprea-Montealegre, J. A., & de Boer, I. H. (2018) · Diabetes Care · doi:10.2337/dci17-0063 · Cited by 11 · see citing works
Long-term Risk of Cardiovascular Events With Rosiglitazone: A Meta-analysis
Singh, S., Loke, Y. K., & Furberg, C. D. (2007) · JAMA · doi:10.1001/jama.298.10.1189 · Cited by 5 · see citing works

Flagged first, then by citations

2 of the 181 references couldn’t be matched to a known paper.

Research works printed but not linked: 11

Bangalore S, Kumar S, Lobach I, Messerli FH. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: ob- servations from traditional and Bayesian ran- dom-effects meta-analyses of randomized trials. Circulation 2011;123:2799-2810
American College of Obstetricians and Gy- necologists; Task Force on Hypertension in Preg- nancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecol- ogists' Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013;122:1122-1131
Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ 2001;323:1213-1217
Webster R, Salam A, de Silva HA, Selak V, Stepien S, Rajapakse S, et al. Fixed low-dose triple combination antihypertensive medication vs usual care for blood pressure control in patients with mild to moderate hypertension in Sri Lanka: a randomized clinical trial. JAMA 2018;320:566- 579
Yusuf S, Teo KK, Pogue J, et al.; ONTARGET Investigators. Telmisartan, ramipril, or both in College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 2018;72:3200-3223
Yusuf S, Bosch J, Dagenais G, et al.; HOPE-3 Investigators. Cholesterol lowering in interme- diate-risk persons without cardiovascular dis- ease. N Engl J Med 2016;374:2021-2031 118.
Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antiox- idants in patients with diabetes and asymptom- atic peripheral arterial disease. BMJ 2008;337: a1840 123.
Bethel MA, Harrison P, Sourij H, et al. Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once- daily aspirin in people with type 2 diabetes. Diabet Med 2016;33:224-230 141.
Zelniker TA, Wiviott SD, Raz I, et al. Com- parison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotrans- porter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation 2019;139: 2022-2031 173.
Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patientswithtype2diabetesmellitus:ameta-analysis of randomized trials. JAMA 2007;298:1180-1188 178.
Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 di- abetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA 2019;321:69-79 185.

Sorted by citations

KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399 · see citing works
Diretrizes Brasileiras de Hipertensão Arterial – 2020
Barroso, W. K. S., Rodrigues, C. I. S., Bortolotto, L. A., Gomes, M. A. M., Brandão, A. A., Feitosa, A. D. M., Machado, C. A., Poli‐de‐Figueiredo, C. E., Amodeo, C., Mion, D., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20201238 · Cited by 1,305 · see citing works
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
Das, S. R., Everett, B. M., Birtcher, K. K., Brown, J. M., Januzzi, J. L., Kalyani, R. R., Kosiborod, M., Magwire, M., Morris, P. B., Neumiller, J. J., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.037 · Cited by 466 · see citing works
Hypertension in Diabetes: An Update of Basic Mechanisms and Clinical Disease
Jia, G., & Sowers, J. R. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.17981 · Cited by 459 · see citing works
2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia
Virani, S. S., Morris, P. B., Agarwala, A., Ballantyne, C. M., Birtcher, K. K., Kris-Etherton, P. M., Ladden-Stirling, A. B., Miller, M., Orringer, C. E., & Stone, N. J. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.06.011 · Cited by 341 · see citing works
Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US
Eberly, L. A., Yang, L., Essien, U. R., Eneanya, N. D., Julien, H. M., Luo, J., Nathan, A. S., Khatana, S. A. M., Dayoub, E. J., Fanaroff, A. C., et al. (2021) · JAMA Health Forum · doi:10.1001/jamahealthforum.2021.4182 · Cited by 288 · see citing works
Ten things to know about ten cardiovascular disease risk factors
Bays, H. E., Taub, P. R., Epstein, E., Michos, E. D., Ferraro, R. A., Bailey, A. L., Kelli, H. M., Ferdinand, K. C., Echols, M. R., Weintraub, H., et al. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100149 · Cited by 274 · see citing works
An Effective Model of Diabetes Care and Education: The ADCES7 Self-Care Behaviors™
Kolb, L. E. (2021) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721720978154 · Cited by 266 · see citing works
CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries
Mosenzon, O., Alguwaihes, A. M., Leon, J. L. A., Bayram, F., Darmon, P., Davis, T. M. E., Dieuzeide, G., Eriksen, K. T., Hong, T., Kaltoft, M. S., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01344-0 · Cited by 249 · see citing works
Diabetes complications in racial and ethnic minority populations in the USA.
Haw, J. S., Shah, M., Turbow, S., Egeolu, M., & Umpierrez, G. (2021) · Current Diabetes Reports · doi:10.1007/s11892-020-01369-x · Cited by 240 · see citing works
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis
Rossing, P. R., Anker, S. D., Filippatos, G. S., Pitt, B., Ruilope, L. M., Birkenfeld, A. L., McGill, J. B., Rosas, S. E., Joseph, A., Gebel, M., et al. (2022) · Diabetes Care · doi:10.2337/dc22-0294 · Cited by 231 · see citing works
Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American Heart Association
Rangaswami, J., Bhalla, V., de Boer, I. H., Staruschenko, A., Sharp, J. A., Singh, R. R., Lo, K. B., Tuttle, K., Vaduganathan, M., Ventura, H., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000920 · Cited by 192 · see citing works
The Evolving Understanding and Approach to Residual Cardiovascular Risk Management
Dhindsa, D. S., Sandesara, P. B., Shapiro, M. D., & Wong, N. D. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00088 · Cited by 200 · see citing works
JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure
Tsutsui, H., Ide, T., Ito, H., Kihara, Y., Kinugawa, K., Kinugawa, S., Makaya, M., Murohara, T., Node, K., Saito, Y., et al. (2021) · Circulation Journal · doi:10.1253/circj.cj-21-0431 · Cited by 189 · see citing works
Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline
Newman, C. B., Blaha, M. J., Boord, J. B., Cariou, B., Chait, A., Fein, H. G., Ginsberg, H. N., Goldberg, I. J., Murad, M. H., Subramanian, S., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa674 · Cited by 180 · see citing works
National Trends in Use of Sodium‐Glucose Cotransporter‐2 Inhibitors and Glucagon‐like Peptide‐1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020
Adhikari, R., Jha, K., Dardari, Z., Heyward, J., Blumenthal, R. S., Eckel, R. H., Alexander, G. C., & Blaha, M. J. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023811 · Cited by 166 · see citing works
Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer
Guirguis‐Blake, J., Evans, C. V., Perdue, L. A., Bean, S., & Senger, C. A. (2022) · JAMA · doi:10.1001/jama.2022.3337 · Cited by 164 · see citing works
Glycemic variability and cardiovascular disease in patients with type 2 diabetes
Martinez, M., Santamarina, J., Pavesi, A., Musso, C., & Umpierrez, G. E. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-002032 · Cited by 155 · see citing works
Guidelines on multidisciplinary approaches for the prevention and management of diabetic foot disease (2020 edition)
Wang, A., Lv, G., Cheng, X., Ma, X., Wang, W., Gui, J., Hu, J., Lu, M., Chu, G., Chen, J., et al. (2020) · Burns & Trauma · doi:10.1093/burnst/tkaa017 · Cited by 153 · see citing works
GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: a systematic review and meta-analysis
Karagiannis, T., Tsapas, A., Athanasiadou, E., Avgerinos, I., Liakos, A., Matthews, D. R., & Bekiari, E. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108737 · Cited by 146 · see citing works
Biomarker-based risk prediction of incident heart failure in pre-diabetes and diabetes
Pandey, A., Vaduganathan, M., Patel, K. V., Ayers, C., Ballantyne, C. M., Kosiborod, M. N., Carnethon, M., DeFilippi, C., McGuire, D. K., Khan, S. S., et al. (2021) · JACC: Heart Failure · doi:10.1016/j.jchf.2020.10.013 · Cited by 144 · see citing works
Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The <scp>PIONEER</scp> programme
Thethi, T. K., Pratley, R., & Meier, J. J. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14054 · Cited by 134 · see citing works
Epidemiology of Diabetes and Atherosclerotic Cardiovascular Disease Among Asian American Adults: Implications, Management, and Future Directions: A Scientific Statement From the American Heart Association
Kwan, T., Wong, S. S., Hong, Y., Kanaya, A. M., Khan, S. S., Hayman, L. L., Shah, S. H., Welty, F. K., DEEDWANIA, P. C., Khaliq, A., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001145 · Cited by 139 · see citing works
A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes
Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Drugs · doi:10.1007/s40265-021-01499-w · Cited by 134 · see citing works
Chronic Kidney Disease Testing Among At-Risk Adults in the U.S. Remains Low: Real-World Evidence From a National Laboratory Database
Alfego, D., Ennis, J. L., Gillespie, B. S., Lewis, M. J., Montgomery, E., Ferrè, S., Vassalotti, J. A., & Letovsky, S. I. (2021) · Diabetes Care · doi:10.2337/dc21-0723 · Cited by 133 · see citing works
Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults
Mackey, K., King, V. J., Gurley, S. B., Kiefer, M., Liederbauer, E., Vela, K., Sonnen, P., & Kansagara, D. L. (2020) · Annals of Internal Medicine · doi:10.7326/m20-1515 · Cited by 129 · see citing works
Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review
Honigberg, M. C., Chang, L.-S., McGuire, D. K., Plutzky, J., Aroda, V. R., & Vaduganathan, M. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.1966 · Cited by 127 · see citing works
Current State of Diabetes Mellitus Prevalence, Awareness, Treatment, and Control in Latin America: Challenges and Innovative Solutions to Improve Health Outcomes Across the Continent
Avilés-Santa, L. M., Monroig-Rivera, A., Soto-Soto, A., & Lindberg, N. M. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01341-9 · Cited by 133 · see citing works
Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug
Nesti, L., Tricò, D., Mengozzi, A., & Natali, A. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01294-7 · Cited by 125 · see citing works
Effects of Vitamin C Supplementation on Glycemic Control and Cardiovascular Risk Factors in People With Type 2 Diabetes: A GRADE-Assessed Systematic Review and Meta-analysis of Randomized Controlled Trials
Mason, S. A., Keske, M. A., & Wadley, G. D. (2021) · Diabetes Care · doi:10.2337/dc20-1893 · Cited by 121 · see citing works
Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes
Deng, X., Zhang, C., Wang, P., Wei, W., Shi, X., Wang, P., Yang, J., Wang, L., Tang, S., Fang, Y., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac210 · Cited by 120 · see citing works
Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial
Ye, N., Jardine, M. J., Oshima, M., Hockham, C., Heerspink, H. J. L., Agarwal, R., Bakris, G., Schutte, A. E., Arnott, C., Chang, T. I., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.048740 · Cited by 115 · see citing works
Exploring the pathophysiology of post-sepsis syndrome to identify therapeutic opportunities
van der Slikke, E. C., An, A. Y., Hancock, R. E. W., & Bouma, H. R. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103044 · Cited by 115 · see citing works
Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes
Ciardullo, S., & Perseghin, G. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154752 · Cited by 111 · see citing works
Risk factors for diabetic foot complications in type 2 diabetes—A systematic review
Rossboth, S., Lechleitner, M., & Oberaigner, W. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.175 · Cited by 109 · see citing works
goFOODTM: An Artificial Intelligence System for Dietary Assessment
Lu, Y. L., Stathopoulou, T., Vasiloglou, M. F., Pinault, L. F., Kiley, C., Spanakis, E. K., & Mougiakakou, S. G. (2020) · Sensors · doi:10.3390/s20154283 · Cited by 108 · see citing works
The Inflammasome in Chronic Complications of Diabetes and Related Metabolic Disorders
Menini, S., Iacobini, C., Vitale, M., & Pugliese, G. (2020) · Cells · doi:10.3390/cells9081812 · Cited by 97 · see citing works
Pros and Cons of Long-Chain Omega-3 Polyunsaturated Fatty Acids in Cardiovascular Health
Djuricic, I. D., & Calder, P. C. (2023) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-051921-090208 · Cited by 101 · see citing works
Role of Glucagon‐Like Peptide‐1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity
Michos, E. D., López-Jiménez, F. A., & Gulati, M. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.029282 · Cited by 91 · see citing works
Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials
Verma, S., McGuire, D. K., Bain, S. C., Bhatt, D. L., Leiter, L. A., Mazer, C. D., Fries, T. M., Pratley, R. E., Rasmussen, S., Vražić, H., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14160 · Cited by 90 · see citing works
Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial
ADDENDA-BHS2 trial investigators, Sposito, A. C., Breder, I. S. S., Soares, A., Kimura-Medorima, S. T., Munhoz, D., Cintra, R. M. R., Bonilha, I., de Oliveira, D. C., Breder, J. D. S. C., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01264-z · Cited by 88 · see citing works
Natural antioxidants in diabetes treatment and management: prospects of astaxanthin
Kanwugu, O. N., Glukhareva, T. V., Danilova, I. G., & Kovaleva, E. G. (2021) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.1881434 · Cited by 90 · see citing works
Effectiveness of combined exercise in people with type 2 diabetes and concurrent overweight/obesity: a systematic review and meta-analysis
Zhao, X., He, Q., Zeng, Y., & Cheng, L. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-046252 · Cited by 82 · see citing works
DRAC 2022: A public benchmark for diabetic retinopathy analysis on ultra-wide optical coherence tomography angiography images
Qian, B., Chen, H., Wang, X., Guan, Z., Li, T., Jin, Y., Wu, Y.-L., Wen, Y., Che, H., Kwon, G., et al. (2024) · Patterns · doi:10.1016/j.patter.2024.100929 · Cited by 82 · see citing works
Individualized Therapy for Hypothyroidism: Is T4 Enough for Everyone?
Ettleson, M. D., & Bianco, A. C. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa430 · Cited by 75 · see citing works
High glucose: an emerging association between diabetes mellitus and cancer progression
Supabphol, S., Seubwai, W., Wongkham, S., & Saengboonmee, C. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02096-w · Cited by 77 · see citing works
Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics
Cernea, S., Dima, L., Correll, C. U., & Manu, P. (2020) · Drugs · doi:10.1007/s40265-020-01393-x · Cited by 74 · see citing works
Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents
The RESPOND Study Group∗ (2021) · AIDS · doi:10.1097/qad.0000000000002811 · Cited by 71 · see citing works
Blood pressure reduction and RAAS inhibition in diabetic kidney disease: therapeutic potentials and limitations
Leoncini, G., Viazzi, F. C., Cosmo, S. D., Russo, G. T., Fioretto, P., & Pontremoli, R. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00803-3 · Cited by 70 · see citing works
Top 10 dietary strategies for atherosclerotic cardiovascular risk reduction
Sikand, G., & Severson, T. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100106 · Cited by 68 · see citing works
Stress-induced hyperglycaemia in non-diabetic patients with acute coronary syndrome: from molecular mechanisms to new therapeutic perspectives
Bellis, A., Mauro, C., Barbato, E., Ceriello, A., Cittadini, A., & Morisco, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020775 · Cited by 61 · see citing works
Legacy effect of intensive glucose control on major adverse cardiovascular outcome: Systematic review and meta-analyses of trials according to different scenarios
Prattichizzo, F., de Candia, P., Nigris, V. D., Nicolucci, A., & Ceriello, A. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154308 · Cited by 64 · see citing works
Euglycemic Diabetic Ketoacidosis and Sodium-Glucose Cotransporter-2 Inhibitors: A Focused Review of Pathophysiology, Risk Factors, and Triggers
Somagutta, M. K. R., Agadi, K., Hange, N., Jain, M. S., Batti, E., Emuze, B. O., Amos-Arowoshegbe, E. O., Popescu, S., Hanan, S., Kumar, V. R., et al. (2021) · Cureus · doi:10.7759/cureus.13665 · Cited by 62 · see citing works
Chronic kidney disease in patients with diabetes mellitus
Nordheim, E., & Jenssen, T. G. (2021) · Endocrine Connections · doi:10.1530/ec-21-0097 · Cited by 69 · see citing works
Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021
Malik, M. E., Falkentoft, A. C., Jensen, J., Zahir, D., Parveen, S., Alhakak, A., Andersson, C., Petrie, M. C., Sattar, N., McMurray, J. J. V., et al. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100617 · Cited by 67 · see citing works
Effectiveness of the chronic care model for adults with type 2 diabetes in primary care: a systematic review and meta-analysis
Goh, L. H., Siah, C. J. R., Tam, W., Tai, E. S., & Young, D. Y. L. (2022) · Systematic Reviews · doi:10.1186/s13643-022-02117-w · Cited by 67 · see citing works
Efficacy of SGLT-2 inhibitors in older adults with diabetes: Systematic review with meta-analysis of cardiovascular outcome trials
Giugliano, D., Longo, M., Maiorino, M. I., Bellastella, G., Chiodini, P., Solerte, S. B., & Esposito, K. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108114 · Cited by 59 · see citing works
Thirty-Year Trends in Complications in U.S. Adults With Newly Diagnosed Type 2 Diabetes
Fang, M., & Selvin, E. (2021) · Diabetes Care · doi:10.2337/dc20-2304 · Cited by 59 · see citing works
The 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the Management of Blood Cholesterol in Diabetes
Goldberg, R. B., Stone, N. J., & Grundy, S. M. (2020) · Diabetes Care · doi:10.2337/dci19-0036 · Cited by 58 · see citing works
The Role of Biofactors in Diabetic Microvascular Complications
Ziegler, D., Porta, M., Παπάνας, Ν., Moța, M., Jermendy, G., Beltramo, E., Mazzeo, A., Caccioppo, A., Striglia, E., Serhiyenko, V. A., et al. (2021) · Current Diabetes Reviews · doi:10.2174/1871527320666210825112240 · Cited by 57 · see citing works
SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies
Mascolo, A., Scavone, C., Scisciola, L., Chiodini, P., Capuano, A., & Paolisso, G. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105836 · Cited by 55 · see citing works
Continuous glucose monitoring in the hospital: an update in the era of COVID-19
Gothong, C., Singh, L. G., Satyarengga, M., & Spanakis, E. K. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000693 · Cited by 58 · see citing works
Diabetes in People with HIV
Sarkar, S., & Brown, T. T. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01382-8 · Cited by 50 · see citing works
Combining Glucagon-Like Peptide 1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors to Target Multiple Organ Defects in Type 2 Diabetes
Anderson, J. E. (2020) · Diabetes Spectrum · doi:10.2337/ds19-0031 · Cited by 49 · see citing works
Disparities in Diabetes Care: Differences Between Rural and Urban Patients Within a Large Health System
Foss, R. M., Fischer, K., Lampman, M. A., Laabs, S. B., Halasy, M. P., Allen, S. V., Garrison, G. M., Sobolik, G. J., Bernard, M., Sosso, J. L., et al. (2023) · The Annals of Family Medicine · doi:10.1370/afm.2962 · Cited by 47 · see citing works
Metformin and cardiorenal outcomes in diabetes: A reappraisal
Petrie, J. R., Rossing, P. R., & Campbell, I. W. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13984 · Cited by 46 · see citing works
Relationship between improvement of glycaemic control and reduction of major cardiovascular events in 15 cardiovascular outcome trials: A meta‐analysis with meta‐regression
Giugliano, D., Bellastella, G., Longo, M., Scappaticcio, L., Maiorino, M. I., Chiodini, P., & Esposito, K. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14047 · Cited by 44 · see citing works
Targeting mitochondrial quality control for diabetic cardiomyopathy: Therapeutic potential of hypoglycemic drugs
Zhou, Y., Suo, W., Zhang, X., Liang, J., Zhao, W., Wang, Y., Li, H., & Ni, Q. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115669 · Cited by 42 · see citing works
AI-based prediction for the risk of coronary heart disease among patients with type 2 diabetes mellitus
Fan, R., Zhang, N., Yang, L., Ke, J., Zhao, D. H., & Cui, Q. (2020) · Scientific Reports · doi:10.1038/s41598-020-71321-2 · Cited by 41 · see citing works
Prevalence of ECG abnormalities in people with type 2 diabetes: The Hoorn Diabetes Care System cohort
Harms, P. P., van der Heijden, A. A. W. A., Rutters, F., Tan, H. L., Beulens, J. W. J., Nijpels, G., & Elders, P. J. M. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107810 · Cited by 41 · see citing works
Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease
Nevola, R., Alfano, M., Pafundi, P. C., Brin, C., Gragnano, F., Calabrò, P., Adinolfi, L. E., Rinaldi, L., Sasso, F. C., & Caturano, A. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2303106 · Cited by 42 · see citing works
Severity and Remission of Metabolic Dysfunction–Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence
Gao, J., Li, Y., Zhang, Y., Zhan, X., Tian, X., Li, J., Wang, R., He, Y. L., Wang, A., & Wu, S. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032604 · Cited by 42 · see citing works
Apolipoprotein B and non-high-density lipoprotein cholesterol reveal a high atherogenicity in individuals with type 2 diabetes and controlled low-density lipoprotein-cholesterol
Fonseca, L., Paredes, S., Ramos, H., Oliveira, J. C., & Palma, I. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01292-w · Cited by 39 · see citing works
Endothelial Dysfunction: A Contributor to Adverse Cardiovascular Remodeling and Heart Failure Development in Type 2 Diabetes beyond Accelerated Atherogenesis
Gamrat, A., Surdacki, M. A., Chyrchel, B., & Surdacki, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072090 · Cited by 38 · see citing works
The Endothelium as a Therapeutic Target in Diabetes: A Narrative Review and Perspective
Adams, J. A., Uryash, A., Lopez, J. R., & Sackner, M. A. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.638491 · Cited by 38 · see citing works
Omega-3 fatty acids for cardiovascular event lowering
Kaur, G., Mason, R. P., Steg, P. G., & Bhatt, D. L. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae003 · Cited by 40 · see citing works
Impact of Longitudinal Virtual Primary Care on Diabetes Quality of Care
Lu, A. D., Gunzburger, E. C., Glorioso, T. J., Smith, W. B., Kenney, R. R., Whooley, M. A., & Ho, P. M. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-020-06547-x · Cited by 35 · see citing works
Outcomes of Cooking Matters for Diabetes: A 6-week Randomized, Controlled Cooking and Diabetes Self-Management Education Intervention
Williams, A., Shrodes, J. C., Radabaugh, J. N., Braun, A. C., Kline, D., Zhao, S., Brock, G. N., Nolan, T. S., Garner, J. A., Spees, C., et al. (2022) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2022.07.021 · Cited by 36 · see citing works
Cardiometabolic Medicine: Development of a New Subspecialty
Saxon, D. R., Reiter–Brennan, C., Blaha, M. J., & Eckel, R. H. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa261 · Cited by 34 · see citing works
Sortilin levels correlate with major cardiovascular events of diabetic patients with peripheral artery disease following revascularization: a prospective study
Biscetti, F., Nardella, E., Rando, M. M., Cecchini, A. L., Bonadia, N., Bruno, P., Angelini, F., Stasi, C. D., Contegiacomo, A., Santoliquido, A., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01123-3 · Cited by 34 · see citing works
Chronic Microvascular Complications in Prediabetic States—An Overview
Baranowska-Jurkun, A., Matuszewski, W., & Bandurska-Stankiewicz, E. M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103289 · Cited by 33 · see citing works
Lipid management for cardiovascular risk reduction in type 1 diabetes
Tell, S., Nadeau, K. J., & Eckel, R. H. (2020) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000551 · Cited by 30 · see citing works
Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis
Castellana, M., Procino, F., Sardone, R., Trimboli, P., & Giannelli, G. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01067-8 · Cited by 31 · see citing works
Effect of sodium–glucose co-transporter-2 inhibitors on the levels of serum asprosin in patients with newly diagnosed type 2 diabetes mellitus
Jiang, A., Feng, Z., Yuan, L., Zhang, Y., Li, Q., & She, Y. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00652-5 · Cited by 31 · see citing works
Diabetes and Dyslipidemia
Feingold, K. R., & Grünfeld, C. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_14 · Cited by 35 · see citing works
Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial
Riddle, M. C., Gerstein, H. C., Xavier, D., Cushman, W. C., Leiter, L. A., Raubenheimer, P. J., Atisso, C. M., Raha, S., Varnado, O. J., Кониг, М., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab065 · Cited by 29 · see citing works
Aspirin for Primary Prevention of Cardiovascular Disease in the 21st Century: A Review of the Evidence
Angiolillo, D. J., & Capodanno, D. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.12.022 · Cited by 29 · see citing works
Prevention and management of cardiovascular disease in patients with diabetes: current challenges and opportunities
Bruemmer, D., & Nissen, S. E. (2020) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000199 · Cited by 29 · see citing works
Recent Updates on Vascular Complications in Patients with Type 2 Diabetes Mellitus
Jung, C., & Mok, J. (2020) · Endocrinology and Metabolism · doi:10.3803/enm.2020.35.2.260 · Cited by 28 · see citing works
Changes in Statin Use Among U.S. Adults With Diabetes: A Population-Based Analysis of NHANES 2011–2018
Leino, A. D., Dorsch, M. P., & Lester, C. A. (2020) · Diabetes Care · doi:10.2337/dc20-1481 · Cited by 28 · see citing works
COVID-19-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes on SGLT2 inhibitor: a case report
Batista, D. V., Vieira, C. A. F. D. A., Costa, T. A., & Lima, E. G. (2020) · Diabetology International · doi:10.1007/s13340-020-00473-3 · Cited by 28 · see citing works
Peripheral artery disease, lower limb revascularization, and amputation in diabetes patients with and without coronary artery disease: a cohort study from the Western Denmark Heart Registry
Olesen, K. K. W., Gyldenkerne, C., Thim, T., Thomsen, R. W., & Mæng, M. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001803 · Cited by 28 · see citing works
Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study
Thomsen, R. W., Knudsen, J. S., Kahlert, J. A., Baggesen, L. M., Lajer, M., Holmgaard, P., Vedin, O., Ustyugova, A., & Sørensen, H. T. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019356 · Cited by 28 · see citing works
Representation and Extrapolation: Evidence from Clinical Trials
Alsan, M. M., Durvasula, M., Gupta, H., Schwartzstein, J., & Williams, H. (2023) · The Quarterly Journal of Economics · doi:10.1093/qje/qjad036 · Cited by 27 · see citing works
Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial
Mosenzon, O., Bain, S. C., Heerspink, H. J. L., Idorn, T., Mann, J. F. E., Persson, F., Pratley, R. E., Rasmussen, S., Rossing, P. R., von Scholten, B. J., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14126 · Cited by 26 · see citing works
Sodium-glucose cotransporter 2 inhibitors’ mechanisms of action in heart failure
Rotkvić, P. G., Berković, M. C., Bulj, N., Rotkvić, L., & Ćelap, I. (2020) · World Journal of Diabetes · doi:10.4239/wjd.v11.i7.269 · Cited by 28 · see citing works
Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial
Shi, A., Xie, P., Nielsen, L. L., Skjøth, T. V., He, X., & Haugaard, S. P. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01548-y · Cited by 28 · see citing works
Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists
Kane, M. P., Triplitt, C. L., & Solis‐Herrera, C. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa413 · Cited by 27 · see citing works
Efficacy of Cinnamon as an Adjuvant in Reducing the Glycemic Biomarkers of Type 2 Diabetes Mellitus: A Three-Month, Randomized, Triple-Blind, Placebo-Controlled Clinical Trial
Neto, J. C. G. L., Damasceno, M. M. C., Ciol, M. A., de Freitas, R. W. J. F., de Araújo, M. F. M., Teixeira, C. R. D. S., Carvalho, G. C. N., Lisboa, K. W. D. S. C., Marques, R. L. L., Alencar, A. M. P. G., et al. (2021) · Journal of the American Nutrition Association · doi:10.1080/07315724.2021.1878967 · Cited by 27 · see citing works
NT-ProBNP and mortality across the spectrum of glucose tolerance in the general US population
Ciardullo, S., Rea, F., Cannistraci, R., Muraca, E., Perra, S., Zerbini, F., Mortara, A., & Perseghin, G. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01671-w · Cited by 27 · see citing works

10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s010 · Cited by 471 · see citing works
Self-citation
9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2018
(2017) · Diabetes Care · doi:10.2337/dc18-s009 · Cited by 490 · see citing works
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s010 · Cited by 495 · see citing works
Self-citation
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s010 · Cited by 869 · see citing works
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Das, S. R., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s010 · Cited by 465 · see citing works

Authors: American Diabetes Association
Venue: Diabetes Care
Publisher: American Diabetes Association
Published: 2019-12-16
Volume: 43
Issue: Supplement_1
Pages: S111-S134
ISSN: 0149-5992 (ISSN-L)
1935-5548
DOI: 10.2337/dc20-s010
OpenAlex: W4254135372
Cited by: 487
References: 181
Citations by year: 2026: 5 · 2025: 20 · 2024: 44 · 2023: 61 · 2022: 89 · 2021: 137 · 2020: 131
FWCI: 72.66
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.diabetesjournals.org/content/license (vor, 4 d)
Locations: Diabetes Care (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords: cardiovascular disease, cardiovascular risk management, diabetes mellitus, clinical guidelines, quality of care
MeSH terms: Heart Disease Risk Factors, Cardiovascular Diseases, Diabetes Mellitus, Diabetic Angiopathies, Endocrinology, Humans, Reference Standards, Societies, Medical, United States, History, 21st Century, Standard of Care

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks